Prediction of Survival Outcome Using Chuang's Prognostic Scale in Metastatic Breast Cancer

Area of Science:

• Oncology
• Clinical Medicine
• Biostatistics

Background:

• Accurate survival estimation is crucial for treatment planning in metastatic breast cancer (MBC), particularly with novel therapies.
• The Chuang's Prognostic Scale (CPS) is a validated tool that can help avoid unnecessary palliative systemic treatments.

Purpose of the Study:

• To evaluate the efficacy of the Chuang's Prognostic Scale (CPS) in predicting survival outcomes for MBC patients.
• To assess CPS performance after at least two lines of palliative systemic chemotherapy protocols (PSCPs).

Main Methods:

• Prospective measurement of CPS in 221 MBC patients, with scores ranging from 0 to 8.5.
• Survival analysis using Kaplan-Meier curves and log-rank tests to compare survival differences between groups.
• Classification of patients into two groups based on a CPS cutoff value of 5.7.

Main Results:

• Patients with CPS ≤5.7 (Group A, 78.7%) had a median survival of 165 days, with 86.2% surviving >3 months.
• Patients with CPS >5.7 (Group B, 21.3%) had a median survival of 81 days, with only 21.3% surviving >3 months (P = 0.00).
• The CPS demonstrated high accuracy for 3-month mortality prediction: sensitivity 97.6%, specificity 98.3%, PPV 93.2%, and NPV 99.4%.

Conclusions:

• The Chuang's Prognostic Scale (CPS) is a valuable tool for estimating survival outcomes in MBC patients.
• CPS can assist clinicians in managing patients who have undergone at least two palliative systemic chemotherapy protocols (PSCPs).